Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Herbal Supplement Found to Curb Growth of Pancreatic Cancer Cells

By Biotechdaily staff writers
Posted on 03 May 2007
A new study suggests that a commonly used herbal supplement, triphala, has cancer-fighting properties that prevent or slow the growth of pancreatic cancer tumors implanted in mice. More...


The study, conducted by investigators from the University of Pittsburgh Cancer Institute (PA, USA), revealed that an extract of triphala, the dried and powdered fruits of three plants, caused pancreatic cancer cells to die through a process called apoptosis--the body's normal process of getting rid of damaged, unwanted, or unneeded cells. This process frequently is broken down in cancer cells. Findings of the study were presented at the annual meeting of the American Association for Cancer Research, April 14-18, 2007, in Los Angeles, CA, USA.

Triphala, one of the most popular herbal preparations in the world, is used for the treatment of intestinal-related disorders. It is usually taken with water and thought to promote appetite and digestion, and to increase the number of red blood cells.

"We discovered that triphala fed orally to mice with human pancreatic tumors was an extremely effective inhibitor of the cancer process, inducing apoptosis in cancer cells,” stated Sanjay K. Srivastava, Ph.D., lead investigator and assistant professor, department of pharmacology, University of Pittsburgh School of Medicine. "Triphala triggered the cancerous cells to die off and significantly reduced the size of the tumors without causing any toxic side effects.”

Dr. Srivastava and colleagues fed mice grafted with human pancreatic tumors 1 to 2 mg of triphala for five days a week, and then compared tumor size and levels of apoptotic proteins in the tumors to a control group of mice that received normal saline only. They discovered that the mice that received triphala had increased levels of proteins associated with apoptosis and considerably smaller tumor sizes when compared to the control group.

Triphala-treated tumors were half the size of tumors in untreated mice. Additional testing demonstrated that triphala activated tumor-suppressor genes, resulting in the production of proteins that support apoptosis, but did not negatively affect normal pancreatic cells.

"Our results demonstrate that triphala has strong anticancer properties given its ability to induce apoptosis in pancreatic cancer cells without damaging normal pancreatic cells,” said Dr. Srivastava. "With follow-up studies, we hope to demonstrate its potential use as a novel agent for the prevention and treatment of pancreatic cancer,” said Dr. Srivastava.


Related Links:
University of Pittsburgh Cancer Institute

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.